Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Liquid Ready-to-use Tumour Marker Control available now from Randox

Published: Thursday, November 22, 2012
Last Updated: Thursday, November 22, 2012
Bookmark and Share
The new Randox Acusera multi-analyte Liquid Tumour Marker Control covers a total of 15 commonly tested and esoteric cancer antigens and tumour markers.

The inclusion of assayed, instrument specific target values enables laboratories to effectively monitor both accuracy and precision.

The Liquid Tumour Marker Control includes AFP (Alpha-fetoprotein), Beta-2- Microglobulin, CA15-3,3xVials01---New-Randox-TM-c.gif CA19-9, CA27-29, CA72-4, CA125, CEA (Carcinoembryonic Antigen), Cyfra 21-1, Ferritin, hCG (Human Chorionic Gonadotropin), NSE (Neuron-specific Enolase), PSA Free (Prostate Specific Antigen Free), PSA Total (Prostate Specific Antigen Total) and Thyroglobulin.

The liquid ready-to-use format is highly convenient for laboratory staff to use requiring no preparation. Furthermore the material can be easily shipped and stored at +2-8oC.  Liquid stable controls not only eliminate the need for reconstitution but reduce the amount of human handling necessary. The user friendly 6 x 3ml pack size and open vial stability of 30 days at +2-8oC for all analytes listed significantly helps to minimise waste and keep running costs low.

Like all Randox immunoassay controls the serum is 100% human in origin providing a matrix similar to the patient sample but also reducing antibody cross reactivity and the possibility of control values shifting when reagent batch is changed. Three distinct levels of control are available with all analytes including PSA present at desirable levels.  Clinically relevant PSA levels ensure the ratio of free to bound PSA is typical of that found in cancer patients.

As a true third party control laboratories can use the Acusera liquid tumour marker control to independently assess analytical performance.  Fully assayed, instrument specific target values and ranges are provided for many common clinical chemistry and immunoassay systems.

For optimum performance and advanced analytical capabilities use in combination with Acusera 24.7 Live Online, an inter-laboratory data management programme designed to monitor analytical performance, interpret QC results and improve the effectiveness of quality control. With Acusera 24.7 users benefit from online access anytime, peer group data generated from thousands of laboratories every 24 hours, fully interactive charts and reports and automatic import of QC data direct from your LIMs or instrument via Acusera 24.7 Connect.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!